Posted by Michael Wonder on 22 Jul 2019
Should national pharmacare apply a value based insurance design?
22 July 2019 - The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, called for universal, single-payer, public pharmacare in Canada.
Private and public drug benefit plans in Canada use numerous forms of out-of-pocket charges for covered prescription drugs. When applied indiscriminately, cost-sharing can reduce patient adherence to medications, even for important classes of drugs such as anti-diabetic mediations. Reduced medication adherence because of cost-sharing can negatively affect the health of vulnerable populations,
The final report of the Advisory Council on the Implementation of National Pharmacare, published in June 2019, called for universal, single-payer, public pharmacare in Canada.
Pharmacare is shaping up to be a defining issue of the 2019 federal election.
